CBCaitlin Brammer

Caitlin Brammer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caitlin Brammer has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Live Attenuated Influenza Vaccine in Pediatric Liver Transplant Recipients: A Retrospective Series

    by Emily Merritt, Caitlin Brammer, William Otto, Anna Borgemenke, Grant Paulsen, Hannah Bahakel, Hilary Miller‐Handley, Kathleen Campbell, Lara Danziger‐Isakov

    Background: Influenza remains a significant cause of morbidity and mortality in pediatric patients, particularly among solid organ transplant (SOT) recipients. Live attenuated influenza vaccines (LAIV) historically have been contraindicated in SOT recipients, with very limited data on the safety of administration after SOT. Methods: We report on the general safety outcomes of a series of four pediatric liver transplant recipients who received LAIV as a part of clinical care between 2019 and 2025 due to prior severe local reaction to the inactivated influenza vaccine (IIV). All patients met specific eligibility criteria for LAIV. Electronic medical records were reviewed. Results: Among 15 administered doses, there were no serious adverse events and only three reports of mild symptoms within the 30 days following vaccination that could not be definitively attributed to LAIV. There were four confirmed influenza infections across two patients that occurred 45 days or more postvaccination; these were mild and did not require emergency department visits or hospitalization. Conclusions: In this cohort of four pediatric liver transplant recipients with severe localized side effects after IIV, LAIV was well‐tolerated without significant safety events, which suggests that safety and immunogenicity of LAIV should be further explored in transplant recipients.

  • Open Access

    Secondary Oral Vancomycin Prophylaxis and Clostridioides difficile Infection in Children and Young Adults With Cancer: A Retrospective Cohort Study

    by Isabela DeJohn, Chunyan Liu, Caitlin Brammer, Maryam Mysorewala, Joshua D Courter, Justin Markham, Soumya Jaiswal, Grant Paulsen, Lara Danziger-Isakov, William R Otto

    Secondary oral vancomycin prophylaxis has been reported to reduce rates of recurrent Clostridioides difficile infection (CDI) in adult patients, but there are limited data in pediatrics. This study sought to assess the impact of secondary oral vancomycin prophylaxis (OVP) during broad-spectrum antibiotic administration in reducing CDI in children and young adults with cancer. This was a retrospective study of children and young adults with cancer with primary CDI episode treated from 2017 to 2024. To determine the causal impact of secondary oral vancomycin prophylaxis during antibiotic administration to prevent CDI in the 6 months after the primary episode, propensity score matching and weighted generalized estimating equations were performed. The initial cohort included 163 patients who experienced primary CDI. After exclusions, 72 patients received 150 courses of broad-spectrum antibiotics within 6 months following their initial infection. Fifteen patients received 27 episodes of OVP. CDIs were not significantly decreased, occurring in 22 of 123 (17.9%) courses in patients who did not receive OVP and 2 of 27 (7.4%) in courses with prophylaxis. Propensity score matching resulted in 49 broad-spectrum antibiotic episodes from 19 patients, forming 11 matched sets. Receipt of OVP was significantly associated with reduced risk of CDI (adjusted odds ratio, 0.074 [95% confidence interval, .01–.54]). In this single-center retrospective study of children and young adults with cancer with primary CDI, receipt of OVP was significantly associated with reduced risk of CDI recurrence when receiving broad-spectrum antibiotic therapy. Given the small sample size and likely residual confounding, these findings should be considered hypothesis-generating pending confirmation in larger studies.